The High-Stakes Battle Over The Future Of Mass Psychedelics
March 25, 2026
Legislators advance two different psychedelic therapy bills, will consider landmark programs for ibogaine and psilocybin
Legislators advance two different psychedelic therapy bills, will consider landmark programs for ibogaine and psilocybin
“… clinically significant and concordant with an emphasis on slow opioid dose reduction over years”
“I stabilized with cannabis and harm reduction and there was absolutely no space for that story in traditional recovery spaces”
“Findings suggest that broadening recreational marijuana access could help address the opioid epidemic.”
Psychedelic-assisted therapy is one approach, but we need to create an ecosystem of options including peer-led support and community-based mental health care
Many cities and towns haven’t spent any opioid abatement dollars. But in some cases, our investigation found that some are using the payments to fund law enforcement
Twenty-seven percent of respondents also said that cannabis reduced their use of other illegal drugs.
“Practical applications for clinical medicine, patients, policy makers, and academics.”
In this free virtual event, the Cannabis Center of Excellence will address policy recommendations with guest Andrew DeAngelo
There are few published clinical trials of psilocybin therapy for chronic pain, although many are ongoing, including a pilot study for fibromyalgia
